Journal Mobile Options
Table of Contents
Vol. 2, No. 5, 2005
Issue release date: February 2006

Increased Cerebrospinal Fluid Aβ38/Aβ42 Ratio in Alzheimer Disease

Mehta P.D. · Pirttila T.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

We quantitated amyloid β peptide (Aβ) 38, Aβ40 and Aβ42 levels in matched CSF and plasma from Alzheimer disease (AD) patients and controls. CSF Aβ38 and Aβ40 levels were similar in AD patients and in controls; however, they were higher in controls with APOE υ4 allele than those without. CSF Aβ42 levels were lower in AD patients than in controls. The CSF Aβ38/42 ratio was higher in AD patients than controls, consistent with the previously reported higher Aβ40/42 ratio. Aβ38, Aβ40 and Aβ42 levels in plasma were similar in AD patients and in controls and showed no relationship to levels in CSF. Our findings suggest that the increased CSF Aβ38/42 ratio found in AD patients is derived entirely from reduction of CSF Aβ42 levels.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Citron M: Strategies for disease modification in Alzheimer’s disease. Nat Rev Neurosci 2004;5:677–685.
  2. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause W, Reulbach U, Kornhuber J, Wiltfang J: Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiol Aging 2004;25:273–281.
  3. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller H-J, Blennow K, Buerger K: Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705–710.
  4. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Rüther E, Kornhuber J: Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481–496.
  5. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, Mehta PD: Amyloid β 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 2005;58:139–142.
  6. Lewczuk P, Esselmann H, Bibl M, Sabine P, Svitek J, Miertschischk J, Meyrer R, Smirnov A, Maler JM, Klein C, Otto M, Bleich S, Sperling W, Kornhuber J, Rüther E, Wiltfang J: Electrophoretic separation of amyloid β peptides in plasma. Electrophoresis 2004;25:3336–3343.
  7. Potempska A, Mack K, Mehta P, Kim KS, Miller DL: Quantification of sub-femtomole amounts of Alzheimer amyloid β peptides. Amyloid 1999;6:14–21.
  8. Mehta PD, Mehta SP, Fedor B, Patrick BA, Emmerling M, Dalton AJ: Plasma amyloid β protein 1–42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett 2003;342:155–158.
  9. Kunicki S, Richardson J, Mehta PD, Kim KS, Zorychta E: The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ) 40, Aβ42, apolipoprotein E and transthyretin in human cerebrospinal fluid. Clin Biochem 1998;31:409–412.
  10. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M: Longitudinal study of cerebrospinal fluid levels of tau, Abeta 1–40, and Abeta 1–42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol 1998;44:17–26.
  11. Mayeux R, Honig LS, Tang M-X, Manly J, Stern Y, Schupf N, Mehta PD: Plasma Aβ40 and Aβ42 and Alzheimer’s disease: relation to age, mortality and risk. Neurology 2003;61:1185–1190.
  12. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP: Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001;304:102–106.
  13. Kuo Y-M, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE: Amyloid-β peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 2000;268:750–756.
  14. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001;414:212–216.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00